Proscia, a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq AP-Dx. The digital pathology solution was cleared for the purpose of primary diagnosis.
Proscia
Proscia’s Concentriq AP-Dx is a diagnostic software solution that immerses pathologists in an intuitive experience for viewing, interpreting, and managing whole slide images and helps to drive confidence and efficiency gains. It can also streamline collaboration, broadening access to expertise. Concentriq AP-Dx was designed to be used in clinical settings of all sizes, from individual reference laboratories to the largest hospital systems.
In support of its 510(k) clearance, Proscia conducted a multi-site clinical study at PathGroup, South Bend Medical Foundation, and Spectrum Healthcare Partners. The study demonstrated that diagnoses made on Concentriq AP-Dx are non-inferior to traditional glass slide reads. Relative to ground truth data, the difference in major discordance rates for slides read digitally and for slides read using the microscope was -0.1%, which is among the strongest findings of similar publicly available studies.
David West, Proscia’s CEO, said: “This regulatory milestone reflects our tireless commitment to our mission of perfecting cancer diagnosis. Pathologists are facing more pressure than ever before in the fight against some of humanity’s biggest challenges. With 510(k) clearance, we can help more laboratories improve the pathologist experience and better serve their patients.”
Up to 70% of clinical decisions depend on pathology. Digital pathology shifts the standard from microscope to high-resolution images each containing over 1 billion pixels that tell the story of a patient’s disease and hold the keys to advancing precision medicine. It is also driving powerful efficiency gains that help laboratories to overcome systemic challenges; hiring for pathologists is near an all-time high as the number of new cancer cases per year in the U.S. is expected to cross 2 million in 2024 for the first time ever.
Proscia has also achieved CE-IVDR certification to advance primary diagnosis in the European Union. The company also has a product licensed in Canada and cleared in the United Kingdom among other countries.
